Pemvidutide Demonstrates Robust MASH Resolution in IMPACT Phase 2b Trial: Clinical Implications of Dual GLP-1/Glucagon Agonism
Posted inDiabetes & Endocrinology Gastroenterology news

Pemvidutide Demonstrates Robust MASH Resolution in IMPACT Phase 2b Trial: Clinical Implications of Dual GLP-1/Glucagon Agonism

The 24-week results of the IMPACT trial show that pemvidutide significantly improves MASH resolution without worsening fibrosis. While fibrosis improvement did not reach significance at this early time point, the drug's safety profile and metabolic efficacy mark a significant step forward in hepatology.
Limited Efficacy for Cabozantinib and Nivolumab in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from a Phase II Trial
Posted inGastroenterology news Oncology

Limited Efficacy for Cabozantinib and Nivolumab in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from a Phase II Trial

A Phase II trial investigating the combination of cabozantinib and nivolumab in advanced extrapancreatic neuroendocrine tumors (epNETs) failed to meet its primary objective response rate endpoint, despite high rates of stable disease, highlighting the challenges of immunotherapy in these tumors.
Adherence to the Planetary Health Diet Index Significantly Lowers MASLD Risk: A Global and Individual-Level Analysis
Posted inGastroenterology news Public Health

Adherence to the Planetary Health Diet Index Significantly Lowers MASLD Risk: A Global and Individual-Level Analysis

A comprehensive study integrating global and individual data reveals that adherence to the Planetary Health Diet Index (PHDI) provides significant protection against metabolic dysfunction-associated steatotic liver disease (MASLD), highlighting a sustainable approach to managing the global liver disease epidemic.
Precision Rechallenge: Liquid Biopsy CGP Refines Patient Selection in Metastatic Colorectal Cancer
Posted inGastroenterology news Oncology

Precision Rechallenge: Liquid Biopsy CGP Refines Patient Selection in Metastatic Colorectal Cancer

The randomized CAVE-2 GOIM trial demonstrates that while adding avelumab to cetuximab rechallenge does not improve survival in metastatic colorectal cancer, liquid biopsy-based genomic hyper-selection identifies a subgroup of patients with significantly improved outcomes, establishing a new standard for precision oncology.
Dual-Action ICyM2 Nano-Platform Dismantles Pancreatic Cancer Stromal Barriers and Ignites STING-Mediated Immunity
Posted inGastroenterology news Oncology

Dual-Action ICyM2 Nano-Platform Dismantles Pancreatic Cancer Stromal Barriers and Ignites STING-Mediated Immunity

Researchers have developed ICyM2, a carrier-free nanoaggregate that combines mitochondrial phototherapy with STING activation. This platform effectively remodels the dense pancreatic cancer stroma, triggers immunogenic cell death, and synergizes with PD-1 inhibitors to convert immunologically 'cold' tumors into 'hot' responsive environments.